TRT and Hormone Marketing Report
Testosterone therapy is a legitimate, high-demand category that happens to share a neighborhood with a grey market of SARMs, anabolic products, and compounded testosterone marketed well outside the rules. That adjacency is what makes hormone marketing risky, and this hub tracks it each quarter with the latest edition on top.
The enforcement record around hormone optimization is not only about the therapy itself. It is about the disease-mongering, the anti-aging promises, and the adjacent products that draw FDA and FTC attention. Meanwhile national brands own the broad searches and the AI answers. Local clinics win on specific, accurate, physician-reviewed authority, and the reports map that opening.
Latest edition · Q2 2026
TRT Marketing, Q2 2026: Enforcement, Search Demand, and AI Visibility
Read the Q2 2026 edition →Other reports
Healthcare Marketing and Compliance Report
The cross-vertical flagship. FDA and FTC enforcement trends alongside search demand and AI-assistant visibility across every regulated healthcare vertical we track.
GLP-1 and Weight Loss Marketing Report
The gold rush and the crackdown. Where GLP-1 and weight-loss demand is going, how enforcement is tightening, and which brands own the AI answers.
Medical Spa and Aesthetics Marketing Report
The most local game in aesthetics. Where med-spa demand concentrates, how product-linked claims draw letters, and how much local ground is still open.
Peptide Marketing Report
The sharpest enforcement edge in the field. Peptides live in an FDA grey zone of 503A and 503B compounding and research-use-only marketing.
Every edition is drawn from the Authoritize Atlas, our corpus of FDA and FTC actions, and from live search and AI-citation measurement. Screen your own marketing against the same rules with the free Claim Checker.